Mycophenolate Mofetil

Used to treat:

Atopic dermatitis
Moderate to severe cases that have not responded to other therapies

What it does: By suppressing the patient's immune system, the medication prevents reactions in the immune system that lead to atopic dermatitis.

What Studies Show
Twenty patients living with long-term atopic dermatitis were given mycophenolate mofetil. None of these patients had responded to other therapies. After receiving mycophenolate mofetil, 17 of the 20 patients improved within 4 weeks of starting therapy. Ten of these patients were able to stop taking the medication and maintain remission. The other seven patients were able to control their atopic dermatitis by taking a maintenance dose. Overall, the medication was well-tolerated. Side effects were mild and included headache and fatigue.

An earlier study produced similar results. Ten patients with moderate to severe atopic dermatitis who had not responded to other treatments were given mycophenolate mofetil. All patients showed significant improvement within 4 weeks. One patient developed a herpes infection in the eye and had to stop treatment. Aside from this, the medication was well-tolerated. Researchers concluded that this medication can be highly effective for treating moderate to severe atopic dermatitis that has not responded to other therapies.

How to use: Available in capsules, a liquid, tablets, and as an injection, this medication must be used as directed.

As mycophenolate mofetil is a powerful immune suppressant, others should not be exposed to this medication. To prevent exposure, the tablets should not be crushed nor opened. The liquid form should not be allowed to touch anyone’s skin.

Grundmann-Kollman M et al. “Mycophenolate mofetil is effective in the treatment of atopic dermatitis.” Archives of Dermatology. 2001. July;137(7):870-873.

Murray ML et al. “Mycophenolate mofetil therapy for moderate to severe atopic dermatitis.” Clinical and Experimental Dermatology. 2006. October 24; [Epub ahead of print].


All content solely developed by the American Academy of Dermatology

Not approved by the U.S. Food and Drug Administration (FDA) for treating atopic dermatitis, mycophenolate mofetil has been approved for preventing organ rejection in transplant patients.





© American Academy of Dermatology, 2010  All rights reserved.

Page last updated 4/4/07

Disclaimer            Copyright Information